nafamostat has been researched along with Anesthesia in 2 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Anesthesia: A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat is a synthetic protease inhibitor with anticoagulant effects." | 5.35 | Nafamostat prevents hypothermia and improves survival time after administration of lipopolysaccharide in a mouse surgical model. ( Adachi, YU; Doi, M; Itagaki, T; Katoh, H; Obata, Y; Sato, S; Suzuki, K, 2009) |
| "Nafamostat is a synthetic protease inhibitor with anticoagulant effects." | 1.35 | Nafamostat prevents hypothermia and improves survival time after administration of lipopolysaccharide in a mouse surgical model. ( Adachi, YU; Doi, M; Itagaki, T; Katoh, H; Obata, Y; Sato, S; Suzuki, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, YU | 1 |
| Obata, Y | 1 |
| Suzuki, K | 1 |
| Katoh, H | 1 |
| Itagaki, T | 1 |
| Doi, M | 1 |
| Sato, S | 1 |
| Ohmizo, H | 1 |
| Iwama, H | 1 |
| Sugita, T | 1 |
2 other studies available for nafamostat and Anesthesia
| Article | Year |
|---|---|
Nafamostat prevents hypothermia and improves survival time after administration of lipopolysaccharide in a mouse surgical model.
Topics: Analysis of Variance; Anesthesia; Anesthetics, Inhalation; Animals; Benzamidines; Body Temperature; | 2009 |
Complement activation by propofol and its effect during propofol anaesthesia.
Topics: Adult; Anesthesia; Anesthetics, Intravenous; Benzamidines; Complement Activation; Complement C3a; Co | 1999 |